Tissue Tolerance of Diclofenac Sodium Encapsulated in Liposomes After Intramuscular Administration

ABSTRACT In this work the effect of the encapsulation of diclofenac sodium within liposomes on the reduction of the myotoxicity after intramuscular administration in rats was studied. Diclofenac sodium was encapsulated in small unilamellar liposomes obtained from phosphatidylcholine, cholesterol, and α-tocopherol (40:10:0.04 mM), and administered by intramuscular injection in the quadriceps femoral muscle of male Wistar rats. After a single dose of 0.2 mg diclofenac formulations the local tissue damage was assessed by plasma creatine kinase (CPK) activity and histological analysis. It was demonstrated that formulations containing free diclofenac produced a higher increase in CPK activity, while those encapsulated in liposomes exhibited CPK activity similar to the control groups. Histopathological analysis of local muscle tissue performed on the third and seventh days following the injection showed intense cellular damage when free drug solution was used, while encapsulation in liposome protected the tissue against the local tissue inflammation.

[1]  V. Diness.  Local tissue damage after intramuscular injections in rabbits and pigs: quantitation by determination of creatine kinase activity at injection sites. , 2009, Acta pharmacologica et toxicologica.

[2]  O. Svendsen,et al.  Tests for local toxicity of intramuscular drug preparations: comparison of in vivo and in vitro methods. , 2009, Acta pharmacologica et toxicologica.

[3]  R. Schiffelers,et al.  Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. , 2001, The Journal of antimicrobial chemotherapy.

[4]  R. B. Campbell,et al.  Influence of cationic lipids on the stability and membrane properties of paclitaxel-containing liposomes. , 2001, Journal of pharmaceutical sciences.

[5]  Adrian C. Williams,et al.  Skin delivery of 5‐fluorouracil from ultradeformable and standard liposomes in‐vitro , 2001, The Journal of pharmacy and pharmacology.

[6]  R. Banerjee,et al.  Liposomes: Applications in Medicine , 2001, Journal of biomaterials applications.

[7]  Y. Kawashima,et al.  Passive targeting of doxorubicin with polymer coated liposomes in tumor bearing rats. , 2001, Biological & pharmaceutical bulletin.

[8]  H. Fessi,et al.  Poly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in rats , 2000, Journal of biomaterials science. Polymer edition.

[9]  A. G. Oliveira,et al.  Piroxicam encapsulated in liposomes: characterization and in vivo evaluation of topical anti-inflammatory effect. , 1999, Drug development and industrial pharmacy.

[10]  D. Lasič.  LIPOSOMES in GENE DELIVERY , 1997 .

[11]  P. Pillans,et al.  Tissue Necrosis and Necrotizing Fasciitis After Intramuscular Administration of Diclofenac , 1995, The Annals of pharmacotherapy.

[12]  M. Olling,et al.  Rabbit model for estimating relative bioavailability, residues and tissue tolerance of intramuscular products: comparison of two ampicillin products. , 1995, Journal of veterinary pharmacology and therapeutics.

[13]  C. Watters,et al.  VENOUS SEQUELAE AFTER I.V. DICLOFENAC , 1991 .

[14]  W. Campbell,et al.  Venous sequelae following i.v. administration of diclofenac. , 1989, British journal of anaesthesia.

[15]  B. Axelsson.  Liposomes as carriers for anti-inflammatory agents , 1989 .

[16]  C. Surber,et al.  Tissue Tolerance of Intramuscular Injectables and Plasma Enzyme Activities in Rats , 1987, Pharmaceutical Research.

[17]  H. Müller-Vahl.  ADVERSE REACTIONS AFTER INTRAMUSCULAR INJECTIONS , 1983, The Lancet.

[18]  J. Watanabe,et al.  The rate of elimination and distribution volume of rabbit muscle creatine phosphokinase. , 1983, Chemical & pharmaceutical bulletin.

[19]  S. Sieber,et al.  Toxicity of free and liposome-encapsulated adriamycin following large volume, short-term intraperitoneal exposure in the rat. , 1982, Toxicology and applied pharmacology.

[20]  R. Wallace.  Is this a practical approach? , 2001, Journal of the American College of Surgeons.

[21]  O. Ringdén,et al.  Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[22]  M. Woodle,et al.  Long Circulating Liposomes: Old Drugs, New Therapeutics , 1998, Biotechnology Intelligence Unit.

[23]  D. Ruff,et al.  CHAPTER 5.2 – Cationic liposomes, DNA and gene delivery , 1998 .

[24]  D. Papahadjopoulos,et al.  CHAPTER 6.1 – Other applications , 1998 .

[25]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[26]  M. Iwaki,et al.  Mechanism for enhancement effect of lipid disperse system on percutaneous absorption. , 1996, Journal of pharmaceutical sciences.

[27]  S. Das,et al.  Effect of Formulation Variables on Dissolution Profile of Diclofenac Sodium from Ethyl- and Hydroxypropylmethyl Cellulose Tablets , 1996 .

[28]  Silvia Stanisçuaski Guterres.  Etude pharmacotechnique, pharmacocinetique et de tolerances digestive et tissulaire des nanocapsules de diclofenac , 1995 .

[29]  D. Hsieh.  Drug Permeation Enhancement - Theory and Applications , 1994 .

[30]  R. New,et al.  Liposomes : a practical approach , 1990 .